Eli Lilly: Oral orforglipron shows superior glycemic control effects in two Phase 3 clinical studies
On October 15th, Eli Lilly announced positive top-line results from the ACHIEVE-2 and ACHIEVE-5 Phase 3 clinical trials. Both studies achieved primary and all key secondary endpoints at week 40, demonstrating significant reductions in A1C, weight loss, and improvements in multiple cardiovascular risk factors, consistent with previously published studies related to type 2 diabetes. Eli Lilly plans to submit a marketing application for orforglipron for type 2 diabetes to global regulatory authorities in 2026, with the application for obesity treatment expected to be submitted by the end of this year
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments